Detailed Narrative
Cenexi Regulatory Headwinds Delay Profitability
The Cenexi business recorded revenue of €41 million in Q3 FY25, which was below management's internal estimates. The primary driver for this miss was an unannounced inspection by the French Health Authority (ANSM) at the Fontenay facility, which disrupted manufacturing for approximately three weeks. Consequently, the timeline for EBITDA breakeven has been pushed back from Q4 FY25 to Q3 FY26. Management is now focused on pushing annual revenue beyond the €200 million threshold to achieve sustainable profitability.
Base Business Margin Resilience Amidst Volume Shifts
Gland's base business (excluding Cenexi) demonstrated strong operational efficiency, with EBITDA margins expanding to 39% from 34% YoY. This improvement occurred despite an 8% YoY revenue decline in the segment, which management attributed to shipping delays for key products like Enoxaparin and Ketorolac. The margin expansion was driven by a favorable product mix, including 13 new molecule launches in the US, and effective cost management measures.
Strategic Pivot to Biologics and CDMO
Management highlighted two major collaborations in the biologics space: a partnership with Dr. Reddy's Laboratories and a new non-binding term sheet with Shanghai Henlius Biotech. To support these initiatives, Gland is evaluating a significant capacity expansion of 15 KL in drug substance manufacturing, with an estimated capex of $80 million to $100 million. Incremental revenue from the Dr. Reddy's collaboration is expected to begin in FY26.
US Market Dynamics and Regulatory Clearance
The company received a major regulatory boost with the receipt of EIRs for its Dundigal and Pashamylaram facilities, successfully closing large-scale US FDA inspections. In the US market, Gland launched 27 molecules and 39 SKUs year-to-date, with new launches contributing approximately 5% of total revenue in Q3. Management remains aggressive in the US, targeting complex generics and RTU (Ready-to-Use) infusion bags to maintain high gross margins.
Geographic Diversification and RoW Strategy
Revenue from Rest of the World (RoW) markets increased to 21% of total revenues. Under the new CEO, Shyamakant Giri, Gland is shifting its RoW strategy from a 'continent lens' to focusing on top-tier high-value countries like Saudi Arabia, Mexico, and South Africa. While a Saudi tender shipment was delayed this quarter, management expects allotment to hospitals to resume in Q4 FY25 or early FY26.